Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) FCF Margin (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed FCF Margin for 7 consecutive years, with 2419.04% as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, FCF Margin rose 88864.0% year-over-year to 2419.04%, compared with a TTM value of 15806.83% through Mar 2024, down 966812.0%, and an annual FY2023 reading of 11276.52%, down 783376.0% over the prior year.
  • FCF Margin was 2419.04% for Q2 2023 at Spyre Therapeutics, up from 8906.06% in the prior quarter.
  • Across five years, FCF Margin topped out at 17.1% in Q2 2021 and bottomed at 10797.62% in Q4 2022.
  • Average FCF Margin over 3 years is 4075.09%, with a median of 2419.04% recorded in 2023.
  • The sharpest move saw FCF Margin plummeted -1026886bps in 2022, then surged 88864bps in 2023.
  • Year by year, FCF Margin stood at 528.76% in 2021, then plummeted by -1942bps to 10797.62% in 2022, then soared by 78bps to 2419.04% in 2023.
  • Business Quant data shows FCF Margin for SYRE at 2419.04% in Q2 2023, 8906.06% in Q1 2023, and 10797.62% in Q4 2022.